#1
|
||||
|
||||
Ралоксифен уменьшает размер лейомиомы
Raloxifene Shrinks Fibroids Through Antiproliferative and Proapoptotic Effects
NEW YORK (Reuters Health) Jul 22 - Previous reports have shown that raloxifene therapy can reduce uterine leiomyomas and now, new research suggests that the mechanism involves antiproliferative and proapototic effects. The findings, which are reported in the July 15th issue of Fertility and Sterility, stem from a study of 40 postmenopausal women with uterine leiomyomas who were scheduled to undergo hysterectomy. Prior to surgery, the women were randomized to receive raloxifene or placebo for 28 days. Ultrasound was used to assess uterine and leiomyoma dimensions before drug therapy and just prior to surgery. Following surgery, the degree of proliferation and apoptosis in the uterine specimens was assessed with PCNA/TC and Bcl-2/Bax cell ratios, respectively. Consistent with previous reports, treatment with raloxifene significantly reduced leiomyoma size compared with baseline values and placebo, lead author Dr. Stafano Palomba, from University "Magna Graecia" in Catanzaro, Italy, and colleagues note. Compared with homologous myometrium, leiomyoma tissue showed greater cell proliferation and less apoptosis, the report indicates. In normal myometrium, cell proliferation was lower in the raloxifene group than in the control group, whereas apoptosis was similar in each group. In leiomyoma tissue, cell proliferation was again lower in the raloxifene group, but apoptosis was higher in the raloxifene group. "The exact mechanism by which raloxifene interacts with cell proliferation and programmed cell death in uterine leiomyomas remains to be investigated," the authors conclude. Fertil Steril 2005;84:154-161. |
#2
|
||||
|
||||
Ралоксифен ( эвиста) зарегистрирован в России как SERM, мы много с ним работали в многоцентровых исследованиях, и я думаю- это хорошая новость. Увы. в пору нашей работы наличие лейомиомы было критерием исключения....
__________________
Г.А. Мельниченко |